

#3
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

EDWARD GREEN ET AL.

SERIAL NO: 09/754,083

FILED: JANUARY 5, 2001

FOR: ETHANOL PRODUCTION

ATTY DKT NO.: 0487.00007

ATTN: BOX MISSING PARTS

TRANSMITTAL OF PRIORITY DOCUMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


Transmitted herewith is a certified copy of U.K. Application No. 0000185.9,
filed January 6, 2000, by the Applicants in the above-captioned application.

Respectfully submitted,

Dated: 16 April 2001

By: Steven P. Schad
Steven P. Schad
Registration No. 32,550

BANNER & WITCOFF, LTD.
1001 G Street, N.W.
Eleventh Floor
Washington, D.C. 20001-4597
(202) 508-9100
385931



INVESTOR IN PEOPLE


#3
The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed



Dated 27 March 2001



The Patent Office

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference JPD/SMH/P10138GB/44621

2. Patent application number
(The Patent Office will fill in this part)

0000185.9

6 JAN 2000

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Agrol Limited
Agrol House
Woodbridge Meadows
Guildford
Surrey
GU1 1BA
United Kingdom

10 JAN 2000 EP06244-1 0000185.9
P01/7771 6/10-0000185.9

7809742001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Ethanol Production

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

WITHERS & ROGERS
Goldings House
2 Hays Lane
London
SE1 2HW

Patents ADP number (if you know it)

1776001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

9. Enter the number of sheets for any of the following claims you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 1 2

Claim(s) 2

Abstract 1

Drawing (s) 6

+ 6 . 

10. If you are also filing any of the following, state how many against each item.

Priority documents


Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.
Signature  Date 6/01/2000

12. Name and daytime telephone number of person to contact in the United Kingdom John Dean 0117 925 3030

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500 505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

JPD/JB/KLB/P10138GB

C:\windows\TEMP\Spec.lwp

ETHANOL PRODUCTION

This invention relates to the production of ethanol as a product of bacterial fermentation. In particular, the invention relates to ethanol production by thermophilic strains of *Bacillus sp.*

Many bacteria have the natural ability to metabolise simple sugars into a mixture of acidic and neutral fermentation products via the process of glycolysis. Glycolysis is the series of enzymatic steps whereby the six carbon glucose molecule is broken down, via multiple intermediates, into two molecules of the three carbon compound pyruvate. The glycolytic pathways of many bacteria produce pyruvate as a common intermediate. Subsequent metabolism of pyruvate results in a net production of NADH and ATP as well as waste products commonly known as fermentation products. Under aerobic conditions, approximately 95% of the pyruvate produced from glycolysis is consumed in a number of short metabolic pathways which act to regenerate NAD^+ via oxidative metabolism, where NADH is typically oxidised by donating hydrogen equivalents via a series of steps to oxygen, thereby forming water, an obligate requirement for continued glycolysis and ATP production.

Under anaerobic conditions, most ATP is generated via glycolysis. Additional ATP can also be regenerated during the production of organic acids such as acetate. NAD^+ is regenerated from NADH during the reduction of organic substrates such as pyruvate or acetyl CoA. Therefore, the fermentation products of glycolysis and pyruvate metabolism include organic acids, such as lactate, formate and acetate as well as neutral products such as ethanol.

The majority of facultatively anaerobic bacteria do not produce high yields of ethanol either under aerobic or anaerobic conditions. Most facultative anaerobes metabolise pyruvate aerobically via pyruvate dehydrogenase (PDH) and the tricarboxylic acid cycle (TCA). Under anaerobic conditions, the main energy pathway for the metabolism of pyruvate is via pyruvate-formate-lyase (PFL) pathway to give formate and acetyl-CoA. Acetyl-CoA is then converted to acetate, via phosphotransacetylase (PTA) and acetate kinase (AK) with the co-production of ATP, or reduced to ethanol via acetaldehyde

dehydrogenase (AcDH) and alcohol dehydrogenase (ADH). In order to maintain a balance of reducing equivalents, excess NADH produced from glycolysis is re-oxidised to NAD⁺ by lactate dehydrogenase (LDH) during the reduction of pyruvate to lactate. NADH can also be re-oxidised by AcDH and ADH during the reduction of acetyl-CoA to ethanol but this is a minor reaction in cells with a functional LDH. Theoretical yields of ethanol are therefore not achieved since most acetyl CoA is converted to acetate to regenerate ATP and excess NADH produced during glycolysis is oxidised by LDH.

Ethanologenic organisms, such as *Zymomonas mobilis* and yeast, are capable of a second type of anaerobic fermentation commonly referred to as an alcoholic fermentation in which pyruvate is metabolised to acetaldehyde and CO₂ by pyruvate decarboxylase (PDC). Acetaldehyde is then reduced to ethanol by ADH regenerating NAD⁺. Alcoholic fermentation results in the metabolism of 1 molecule of glucose to two molecules of ethanol and two molecules of CO₂. DNA which encodes both of these enzymes in *Z. mobilis* has been isolated, cloned and expressed recombinantly in hosts capable of producing high yields of ethanol via the synthetic route described above. For example; US 5,000,000 and Ingram *et al* (1997) *Biotechnology and Bioengineering* 58, Nos. 2 and 3 have shown that the genes encoding both PDC (*pdc*) and ADH (*adh*) from *Z. mobilis* can be incorporated into a "pet" operon which can be used to transform *Escherichia coli* strains resulting in the production of recombinant *E. coli* capable of co-expressing the *Z. mobilis* *pdc* and *adh*. This results in the production of a synthetic pathway re-directing *E. coli* central metabolism from pyruvate to ethanol during growth under both aerobic and anaerobic conditions. Similarly, US 5,554,520 discloses that *pdc* and *adh* from *Z. mobilis* can both be integrated via the use of a pet operon to produce Gram negative recombinant hosts, including *Erwinia*, *Klebsiella* and *Xanthomonas* species, each of which expresses the heterologous genes of *Z. mobilis* resulting in high yield production of ethanol via a synthetic pathway from pyruvate to ethanol.

US 5,482,846 discloses the simultaneous transformation of Gram positive *Bacillus sp* with heterologous genes which encode both the PDC and ADH enzymes so that the transformed bacteria produce ethanol as a primary fermentation product. There is no suggestion that the bacteria may be transformed with the *pdc* gene alone.

A key improvement in the production of ethanol using biocatalysts can be achieved if operating temperatures are increased to levels at which the ethanol is conveniently removed in a vapourised form from the fermentation medium. However, at the temperatures envisioned, traditional mesophilic microorganisms, such as yeasts and *Z. mobilis*, are incapable of growth. This has led researchers to consider the use of thermophilic, ethanologenic bacteria as a functional alternative to traditional mesophilic organisms. See EP-A-0370023.

The use of thermophilic bacteria for ethanol production offers many advantages over traditional processes based upon mesophilic ethanol producers. Such advantages include the ability to ferment a wide range of substrates, utilising both cellobiose and pentose sugars found within the dilute acid hydrolysate of lignocellulose, as well as the reduction of ethanol inhibition by continuous removal of ethanol from the reaction medium using either a mild vacuum or gas sparging. In this way, the majority of the ethanol produced may be automatically removed in the vapour phase at temperatures above 50°C allowing the production phase to be fed with high sugar concentrations without exceeding the ethanol tolerance of the organism, thereby making the reaction more efficient. The use of thermophilic organisms also provides significant economic savings over traditional process methods based upon lower ethanol separation costs.

The use of facultative anaerobes also provides a number of advantages in allowing a mixed aerobic and anaerobic process. This facilitates the use of by-products of the anaerobic phase to generate further catalytic biomass in the aerobic phase which can then be returned to the anaerobic production phase.

The inventors have produced sporulation deficient variants of a thermophilic, facultatively anaerobic, Gram-positive bacterium which exhibit improved ethanol production-related characteristics.

This approach has a number of important advantages over conventional processes using both traditional and recombinant mesophilic bacteria, including simplification of the transformation process by using only the *pdc* gene of *Z. mobilis* in strains that already produce ethanol and have a 'native' *adh* gene. Expression of *pdc* has resulted in a

significant increase in ethanol production by the recombinant organism and has unexpectedly improved the organism's growth characteristics. Recombinant microorganisms, which prior to transformation with the *pdc* gene were highly unstable and difficult to culture, show significant increases in growth and survival rates both aerobically and anaerobically at temperatures between 50- 70°C as well as an increase in the rate of ethanol production near to theoretical yields.

Accordingly, a first aspect of the invention relates to a Gram-positive bacterium which has been transformed with a heterologous *pdc* gene, but which has solely a native alcohol dehydrogenase function. The gene may encode a functional equivalent of pyruvate decarboxylase. Functional equivalents of pyruvate decarboxylase include expression products of insertion and deletion mutants of natural *pdc* gene sequences.

It is possible that organisms which carry out glycolysis or a variant thereof can be engineered, in accordance with the present invention, to convert as much as 67% of the carbon in a sugar molecule via glycolysis and a synthetic metabolic pathway comprising enzymes which are encoded by heterologous *pdc* and native *adh* genes. The result is an engineered organism which produces ethanol as its primary fermentation product.

The Gram-positive bacterium is preferably a *Bacillus*. The bacterium may be a thermophile. Where the Gram-positive bacterium is a *Bacillus* it is preferably selected from *B. stearothermophilus*; *B. calvodox*; *B. caldotenax*; *B. thermoglucosidasias*, *B. coagulans*, *B. licheniformis*, *B. thermodenitrificans*, and *B. caldolyticus*.

A gene encoding lactate dehydrogenase may be inactivated in the Gram-positive bacterium of the invention. For example, the lactate dehydrogenase gene may be inactivated by homologous recombination.

The heterologous *pdc* gene may be from *Zymomonas sp*, preferably *Z. mobilis* or may be from yeast e.g the *S. cerevisiae pdc 5* gene.

The heterologous gene may be incorporated into the chromosome of the bacterium. Alternatively, the bacterium may be transformed with a plasmid comprising the

heterologous gene. The invention includes Gram-positive bacteria, preferably a *Bacillus sp* including the operon of the invention. The *Bacillus sp* may be selected from *B. stearothermophilus*; *B. calvodex*; *B. caldotenax*, *B. thermoglucosidasias*, *B. coagulans*, *B. licheniformis*, *B. thermodenitrificans*, and *B. caldolyticus*. The operon may be incorporated into the genome of the *Bacillus*. Multiple copies of the PDC operon may be incorporated into the genome.

The invention also provides strains LN (NCIMB accession number); LN-T (E31, E32); TN (NCIMB accession number); TN-P1; LN-S (J8) (NCIMB accession number); LN-D (NCIMB accession number); LN-D11 and LN-P1.

According to another aspect of the invention, there is provided a recombinant, sporulation deficient, thermophilic *Bacillus* which grows at greater than 50°C. The *Bacillus* is preferably not *B. licheniformis*.

A second aspect of the present invention relates to a method of producing either ethanol or L-lactic acid using bacteria of the invention maintained under suitable conditions.

The method may be operated at a temperature between 40-75°C; preferably at a temperature of 52-65°C; most preferably at a temperature of 60-65°C.

The production of recombinant bacteria in accordance with the invention will now be described, by way of example only, with reference to the accompanying drawings, Figures 1 to 6 in which:

Fig. 1 is a schematic representation showing the production of bacterial strains of the invention;

Fig. 2 illustrates the metabolic pathway whereby sugars are metabolised to produce ethanol by bacterial strains of the invention;

Fig. 3 is a schematic representation illustrating the method of LDH gene inactivation by single crossover recombination;

Fig. 4 is a schematic representation illustrating the method of LDH gene inactivation by double crossover recombination;

Fig. 5 is a schematic representation illustrating the method of LDH gene inactivation and heterologous gene expression by double crossover recombination; and

Fig. 6 shows the construction of an artificial PDC operon.

The inventors initiated a strain development program to overcome inherent strain limitations in respect of ethanol production, such as instability and sporulation under adverse conditions. Physiological manipulation and selection for strains with superior growth characteristics has been achieved in continuous culture, whereas a more targeted genetic approach has been used to engineer strains with greater stability and superior production characteristics.

In accordance with Figure 1, all strains were ultimately derived from a previously isolated *Bacillus* isolate PSII, a novel, thermophilic, Gram-positive, spore-forming, facultative anaerobe. PSII ferments a wide range of organic compounds from sugars, including hemicelluloses, to organic acids such as acetate, formate and lactate and small amounts of ethanol at temperatures between 50°C and 70°C.

Bacillus strains LLD-15, LLD-R, LLD-16 and T13 have been described in EP-A-0370023 and by Amartei *et al*, (1999) *Process Biochemistry* 34 No. 3 pp.289-294. Strain LLD-15 (NCIMB12428) arose during attempts to obtain mutants of *Bacillus stearothermophilus* strain NCA 1503 lacking L-LDH activity by selecting for suicide substrate resistance (Payton and Hartley (1984) *Trends in Biotechnology*, 2 No. 6). Strain LLD-15 was assumed to be a variant of *B. stearothermophilus* NCA1503, but is, in fact, derived from PS11. Strain LLD-R arises spontaneously and reproducibly from strain LLD-15 and is selected on plates or during continuous cultures under which it grows more rapidly (i.e. at low pH in media containing sugars, acetate and formate). LLD-R produces L-lactate anaerobically and contains high levels of L-LDH, so is therefore, clearly a wild type revertant of the non-lactate-producing LLD-15 lesion.

Bacillus strain T13 is an L-lactate deficient mutant of strain LLD-R. Isolation and characterisation of this mutant strain has been described previously by, Javed. M. PhD Thesis, Imperial College, London. Thus, *Bacillus* strains LLD-15, LLD-16 and T13 are mutants of the original isolate, PSII in which the *ldh* gene has been inactivated either via spontaneous mutation or by chemical mutagenesis and the major fermentation product, unlike PSII, is ethanol. The lactate dehydrogenase gene mutation in LLD-15, LLD-16 and T13 results from the insertion of a transposon into the coding region of the lactate dehydrogenase gene resulting in *ldhT* geno-type. All three strains are inherently unstable in high sugar concentrations (>2%) and revert back to lactate producing strains. Strains T-13 and LLD-15 revert to T13-R and LLD-R, respectively. Strains LLD-15, LLD-R, LLD-16 and T13 also tend to sporulate under adverse growth conditions such as changes in pH, temperature and medium compositions, and during periods of nutrient starvation. Since sporulation often leads to culture washout in a continuous system, these strains are not suitable for large scale industrial use in which process parameters fluctuate.

Example 1

Production of LN

Bacillus strain LN was produced from LLD-R as a spontaneous mutant which arose during nitrogen adaptation in continuous culture. Strain LN is more robust than the parental strains LLD-15 and LLD-R under vigorous industrial conditions such as low pH, high sugar concentrations and in crude hydrolysate feed stocks and is more amenable to plasmid transformation. Strain LN is sporulation deficient (*spo*⁻) and is particularly suitable for the production of high purity L-lactic acid, producing up to 0.4g of L-lactate/g of glucose at 65°C. This strain is sensitive to kanamycin concentrations in excess of 5µg/ml and an ideal host for genetic manipulation (*ldh* inactivation and heterologous gene expression). Strain LN has been deposited under the terms of the Budapest Treaty under accession No.

Example 2

Production of Strain LN-T

Strains E31 and E32 are spontaneous transposon mutants from strain LN. Both strains are lactate deficient and produce up to 0.4g of ethanol/g of glucose at 65°C. They are non-sporulating and as such more amenable to genetic manipulation than T13.

Example 3**Production of Strain LN-S (J8)**

Strain LN-S (J8) was produced by a single crossover recombination event between a temperature sensitive, non-replicative plasmid harbouring an internal region of the *ldh* gene and the *ldh* gene on the chromosome (see Figure 3). This resulted in inactivation of the *ldh* gene and a lactate negative phenotype. This strain is also sporulation deficient and resistant to kanamycin. It is stable in relatively high sugar concentrations in continuous culture (with 10g/L of residual sugar), it has good growth characteristics and produces relatively high yields of ethanol. For example, in continuous culture at pH 7.0, 65°C, dilution rate of 0.1h⁻¹, and 50g/L glucose feed, the cells produce up to 0.4g of ethanol/g of glucose utilised for 200 hours or more without any drop in ethanol yield.

Strain LN-S (J8) has been deposited with the NCIMB under the terms of the Budapest Treaty under accession number.....

Example 4**Production of Strain LN-D**

This strain was produced by a double crossover recombination event between a linear insertion cassette and the *ldh* gene from strain LN (see Figure 4). Recombination inactivated both the *ldh* and lactate permease (*lp*) genes resulting in a lactate negative phenotype. This strain is also sporulation deficient and resistant to kanamycin. Strain LN-D can tolerate high sugar concentrations (with up to 10g/L of residual sugar), it has good growth characteristics and produces relatively high yields of ethanol. For example, in continuous culture at pH 7.0, 52°C, dilution rate of 0.1h⁻¹, and 50g/L glucose feed, the cells produce up to 0.4g of ethanol/g of glucose utilised for 200 hours or more without any drop in ethanol yield or cell viability. Furthermore, kanamycin selection was not required to maintain the *ldh* gene inactivation.

Strain LN-D has been deposited with the NCIMB under the terms of the Budapest Treaty under accession number.....

Example 5**Production of Strain LN-D11**

The resistance of strain LN-D to kanamycin was cured after repeated subculture to produce strain LN-D11. This strain is lactate negative, sporulation deficient and sensitive to kanamycin concentrations in excess of 5µg/ml. Strain LN-D11 can tolerate high sugar concentrations (with up to 10g/L of residual sugar), it has good growth characteristics and produces relatively high yields of ethanol. For example, in continuous culture at pH 7.0, 52°C, dilution rate of 0.1h⁻¹, and 50g/L glucose feed, the cells produce up to 0.4g of ethanol/g of glucose utilised for 200 hours or more without any drop in ethanol yield or cell viability. This strain is an ideal host for heterologous gene expression.

Example 6**Production of Strain LN-vDP1**

Strain LN-DP1 was produced from strain LN-D11 after transformation with plasmid pZP1. The backbone of this vector is pBST22 (originally developed by Liao *et al* (1986) *PNAS* (USA) **83**: 576-580) with the entire *pdh* gene from *Z. mobilis* under the control of the *ldh* promoter sequence from *B. stearothermophilus* NCA 1503. Strain LN-vDP1 is sporulation deficient; kanamycin resistant, lactate negative and contains the heterologous *pdh* gene from *Z. mobilis*. Strain LN-vDP1 can utilise high sugar concentrations, it has good growth characteristics and produces relatively high yields of ethanol. For example, in continuous culture at pH 7.0, 60°C, dilution rate of 0.1h⁻¹, and 50g/L glucose feed, the cells produce up to 0.45g of ethanol/g of glucose utilised for 200 hours or more without any drop in ethanol yield.

Example 7**Production of Strain TN**

Strain TN arose spontaneously from T13 during nitrogen adaptation in continuous culture. This strain is more robust than the parental strain under vigorous industrial conditions (i.e. low pH, high sugar concentrations, and in crude hydrolysate feed stocks) and is more amenable to plasmid transformation, making it an ideal host for genetic engineering. Strain TN is sporulation deficient and lactate negative (the *ldh* gene has been inactivated by transposon mutagenesis into the coding region of the *ldh* gene). Strain TN is a good ethanol producer on dilute sugar feeds. For example, in continuous culture at pH 7.0, 70°C, dilution rate of 0.1h⁻¹, and 20g/L glucose, the cells produce up to 0.4g of ethanol/g of

glucose for 100 hours or more without any drop in ethanol yield. This strain is sensitive to kanamycin concentrations in excess of 5µg/ml and an ideal host for genetic manipulation.

Strain TN has been deposited at the NCIMB under the terms of the Budapest Treaty under accession number.....

Example 8

Production of Strain TN-P1

Strain TN-P1 was produced from strain TN after transformation with plasmid pZP1. As previously described, pZP1 was produced by the incorporation of a *pdg* gene in vector pBST22. The transformation efficiency of TN was 10-fold higher with pZP1 than pBST22 and the colony size of the transformants were significantly larger indicating that *pdg* expression conferred a growth advantage to the cells.

TN-P1 is also more stable and a better ethanol producer than TN, especially in sugar concentrations greater than 20g/L. For example, in continuous culture controlled at pH 7.0, 52°C with a dilution rate of 0.1h⁻¹, and a sugar feed containing 20-50 g/L, strain TN-P1 produced up to 0.45g ethanol/g sugar utilised for 600 hours with no significant drop in yield or cell viability. In addition, in continuous culture controlled at pH 7.0, 52°C with a dilution rate of 0.1h⁻¹, and a wheat crude hydrolysate feed, TN-P1 produced 0.4 g ethanol/g sugar utilised in for 400 hours with no significant drop in ethanol yield or culture viability.

Plasmid selection in strain TN-P1 was first maintained with kanamycin but the plasmid was found to be relatively stable without selection and no significant plasmid loss was detected after 300 hours of continuous culture. The plasmid and PDC enzyme were found to be relatively stable at high temperatures. In continuous culture controlled at pH 7.0, with a dilution rate of 0.1h⁻¹, and a glucose feed of 30g/L, there was no significant drop in ethanol yield or culture viability when the growth temperature was increased from 52 to 64°C.

Gene Inactivation

Single-Crossover Recombination (SCO) (Figure 3)

SCO or Campbell-type integration was used for directed *ldh* gene inactivation. An internal fragment (700 bp) of the target gene (*ldh*) was first cloned into pUBUC to form pUBUC-LDH.

Plasmid pUBUC is a shuttle vector for DNA transfer between *Escherichia coli* and *Bacillus* strains LN and TN and was formed from the fusion of pUB110 and pUC18. This vector contains a selectable marker that confers resistance to kanamycin and a Gram-positive and Gram-negative replicon. The plasmid is temperature sensitive in *Bacillus* and cannot replicate above 54°C.

Plasmid pUBUC-LDH was first methylated (*in vivo*) and then transformed into the host strain (LN) at the permissible temperature (50°C) for plasmid propagation. The growth temperature was then increased to 65°C, preventing plasmid replication and integrants were selected using kanamycin. Integration of the plasmid DNA into the *ldh* gene resulted in gene inactivation and a lactate negative phenotype.

Double-Crossover Recombination (DCO) (Figures 4 & 5)

DCO or replacement recombination differs from SCO in that it results in integration of only one copy of the target DNA and typically, a region of chromosomal DNA is replaced by another region, either foreign DNA or mutationally altered homologous DNA. The target DNA (kanamycin marker) was flanked on either side by mutationally altered fragments of the *ldh* gene in plasmid pUC-IC (a non-replicative vector based on pUC18). The vector was first methylated (*in vivo*) and then linearised at a site outside the flanking region (this prevents SCO). The methylated, linearised plasmid DNA was then transformed into strain LN and integrants were selected using kanamycin.

This technique can also be used to inactivate *ldh* and integrate a copy of the *pdc* gene (or any other gene of interest) into the chromosome simultaneously (Figure 5).

Development of an Artificial PDC operon

An artificial PDC operon can be constructed using interchangeable gene sequences from the *ldh* promoter, *pdh* genes from *Z. mobilis* and the yeast *Saccharomyces cerevisiae*, and *adh* from LLD-R (see Figure 6).

- 1) *pdh* expression should be increased when the *ldh* promoter from *B. stearothermophilus* NCA1503 is replaced by the *ldh* promoter from LLD-R and will result in higher ethanol yields.
- 2) the ethanol yields should be increased further if *adh* from LLD-R is co-expressed with *pdh* from *Z. mobilis* in a PDC operon Ethanol yields should be close to theoretical values of 0.5g ethanol/g sugar.
- 3) the thermostability of *pdh* may be increased above 64°C if the *Z. mobilis pdh* gene is replaced by the *pdh5* gene from *S. cerevisiae*. This will increase the growth temperature from 64 to 70°C.

Integration of the PDC operon into strain LN-D11

By fusing the PDC operon to the insertion element sequence (first identified in the *ldh* gene from TN) several copies of the PDC operon can be introduced into multiple sites on the chromosome increasing both the stability and gene dosage.

This expression strategy may also be used for other genes of interest.

Claims

1. A Gram-positive bacterium which has been transformed with a heterologous gene encoding pyruvate decarboxylase or a functional equivalent thereof, but has solely native alcohol dehydrogenase function.
2. A Gram-positive bacterium according to claim 1 wherein the bacterium is a *Bacillus sp.*
3. A Gram-positive bacterium according to claim 1 or 2 wherein the bacterium is a thermophile.
4. A Gram-positive bacterium according to claim 2 or 3 wherein the *Bacillus* is selected from *B. stearothermophilus*; *B. calvodox*; *B. caldotenax*, *B. thermoglucosidasias*, *B. coagulans*, *B. licheniformis*, *B. thermodenitrificans*, and *B. caldolyticus*.
5. A Gram-positive bacterium according to claim 1, 2, 3 or 4 wherein the gene encoding lactate dehydrogenase expression has been inactivated.
6. A Gram-positive bacterium according to claim 5 in which the lactate dehydrogenase gene has been inactivated by homologous recombination.
7. A Gram-positive bacterium according to any preceding claim in which the heterologous gene is from *Zymomonas sp* or from *Saccharomyces cerevisiae*.
8. A Gram-positive bacterium according to claim 7 in which the heterologous gene is from *Z. mobilis*.
9. A Gram-positive bacteria according to claim 7 in which the heterologous gene is *pdh* 5 from *S. cerevisiae*.
10. A Gram-positive bacterium according to the preceding claim wherein the heterologous gene is incorporated into the chromosome of the bacterium.

11. A Gram-positive bacterium according to any one of claims 1 to 9 in which the bacterium has been transformed with a plasmid comprising the heterologous gene.
12. Strains LN (NCIMB accession number); LN-T (E31, E32); TN (NCIMB accession number); TN-P1; LN-S (J8) (NCIMB accession number); LN-D (NCIMB accession number); LN-D11 and LN-P1.
13. A recombinant, sporulation deficient, thermophilic *Bacillus* which grows at greater than 50°C.
14. A recombinant sporulation deficient, thermophilic *Bacillus* which grows at greater than 50°C and which is not *B. licheniformis*.
15. A method of producing ethanol comprising culturing a bacterium or strain according to any one of claims 1 to 12 under suitable conditions.
16. A method according to claim 15 in which the method is operated at a temperature between 40- 75 °C.
17. A method according to claim 16 operated at a temperature of 52-65 °C
18. A method according to claim 16 operated at a temperature of 60-65 °C.
19. A method of producing L-lactic acid comprising culturing a bacterium according to any one of claims 1 to 12 under suitable conditions.

ETHANOL PRODUCTION

This invention relates to ethanol production as a product of bacterial fermentation.

Figure 1.




Figure 2.




Figure 3.

LDH Gene Inactivation by Single-Crossover Recombination





Figure 4.


LDH Gene Inactivation by Double-Crossover Recombination




The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry, no matter how small, should be recorded to ensure the integrity of the financial data. This includes not only sales and purchases but also expenses and income. The second part of the document provides a detailed breakdown of the company's financial performance over the past year. It includes a comparison of actual results against budgeted figures, highlighting areas of strength and areas needing improvement. The third part of the document outlines the company's financial goals for the upcoming year, including targets for revenue, profit, and cash flow. It also discusses the strategies and initiatives that will be implemented to achieve these goals. The final part of the document provides a summary of the key findings and recommendations, emphasizing the need for continued vigilance and attention to financial management.

Figure 5.

LDH Gene Inactivation and Heterologous Gene Expression by Double-Crossover Recombination



Construction of an Artificial PDC operon



Expression Strategy

- 1) Plasmid-borne expression
 - pUBUC
 - pBST22
- 2) Transposon mediated integration
- 3) LDH inactivation and homologous integration

Fig. 6

